FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 834 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Misdiagnosis: Her Doctor Dismissed Her Concerns For Months Then Told Her... June 2, 2020 Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients... February 25, 2025 With Longer Follow-Up, Trastuzumab Deruxtecan Continues to Demonstrate Superior Efficacy Over... June 27, 2024 El cáncer en mi comunidad: Cómo superar las desigualdades en la... January 3, 2023 Load more HOT NEWS Navigating Life During and After Cancer As a Young Adult: A... NCI and CRUK Take on Cancer’s Toughest Problems FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma What to Know When Searching for Cancer Information Online: An Expert...
